XWELL, Inc.
For the period ended Aug 14, 2025. Filed Aug 14, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Aug 14, 2025 · Filed Aug 14, 2025
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Biosurveillance Program
Biosurveillance Program
Through XpresCheck and HyperPointe, XWELL continues to operate at the frontlines of biosurveillance and digital healthcare infrastructure.
In March 2025, XWELL secured a three-year extension of its Traveler-based Genomic Surveillance Program (“TGS”), operated with the CDC and Ginkgo Bioworks Holdings. The TGS program, provides early detection of emerging pathogens, safeguarding national health through airport-based biosurveillance.
XpresCheck, which helped power national COVID-19 testing and reporting during the pandemic, and HyperPointe serve as the operational and technological core of this next phase of strategic, science-driven wellness program.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.